EA201691251A1 - Цитотоксические пептиды и их конъюгаты - Google Patents

Цитотоксические пептиды и их конъюгаты

Info

Publication number
EA201691251A1
EA201691251A1 EA201691251A EA201691251A EA201691251A1 EA 201691251 A1 EA201691251 A1 EA 201691251A1 EA 201691251 A EA201691251 A EA 201691251A EA 201691251 A EA201691251 A EA 201691251A EA 201691251 A1 EA201691251 A1 EA 201691251A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunoconjugates
antibody
peptides
conjugates
addition
Prior art date
Application number
EA201691251A
Other languages
English (en)
Inventor
Бернхард Гайерштангер
Ян Груневальд
Вэйцзя Оу
Тецуо Уно
Юнцинь Ван
Син Ван
Юнхо Дзин
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201691251A1 publication Critical patent/EA201691251A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Предложены новые цитотоксические пептиды формулы (I), описанные в настоящем документе:и применение таких пептидов при получении иммуноконъюгатов (т.е. конъюгатов антитело-лекарственное средство). Кроме того, описаны иммуноконъюгаты (т.е. конъюгаты антитело-лекарственное средство), содержащие такой новый цитотоксический пептид, связанный с антигенсвязывающим фрагментом, таким как антитело; где указанные иммуноконъюгаты могут быть использованы для лечения клеточных пролиферативных нарушений. Кроме того, изобретение относится к фармацевтическим композициям, содержащим эти иммуноконъюгаты, композициям, содержащим иммуноконъюгаты с терапевтическим соагентом, и способам применения указанных иммуноконъюгатов и композиций для лечения клеточных пролиферативных нарушений.
EA201691251A 2013-12-17 2014-12-17 Цитотоксические пептиды и их конъюгаты EA201691251A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917293P 2013-12-17 2013-12-17
PCT/US2014/070800 WO2015095301A2 (en) 2013-12-17 2014-12-17 Cytotoxic peptides and conjugates thereof

Publications (1)

Publication Number Publication Date
EA201691251A1 true EA201691251A1 (ru) 2016-11-30

Family

ID=52463118

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691251A EA201691251A1 (ru) 2013-12-17 2014-12-17 Цитотоксические пептиды и их конъюгаты

Country Status (16)

Country Link
US (3) US9988420B2 (ru)
EP (2) EP3753578A1 (ru)
JP (2) JP6636925B2 (ru)
KR (1) KR20160098257A (ru)
CN (1) CN105899526A (ru)
AU (1) AU2014364812B2 (ru)
BR (1) BR112016012538A2 (ru)
CA (1) CA2930614A1 (ru)
EA (1) EA201691251A1 (ru)
ES (1) ES2758506T3 (ru)
IL (1) IL245558B (ru)
MX (1) MX2016007865A (ru)
PL (1) PL3082877T3 (ru)
PT (1) PT3082877T (ru)
SG (1) SG11201604877UA (ru)
WO (1) WO2015095301A2 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015010146A (es) * 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
CN110143999B (zh) 2013-03-15 2023-12-05 酵活英属哥伦比亚省公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
AU2014373574B2 (en) 2013-12-27 2020-07-16 Zymeworks Bc Inc. Sulfonamide-containing linkage systems for drug conjugates
US10675355B2 (en) 2013-12-27 2020-06-09 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
SG11201606850QA (en) * 2014-03-12 2016-09-29 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2015189791A1 (en) 2014-06-13 2015-12-17 Novartis Ag Auristatin derivatives and conjugates thereof
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
UY38265A (es) * 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
WO2020103891A1 (en) * 2018-11-23 2020-05-28 Wuxi Biologics (Shanghai) Co. Ltd. ortho-Phthalaldehyde containing linkers and use for preparation of antibody-drug conjugate
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2022154127A1 (ja) * 2021-01-18 2022-07-21 味の素株式会社 化合物またはその塩、およびそれらにより得られる抗体
WO2023061405A1 (zh) * 2021-10-12 2023-04-20 成都科岭源医药技术有限公司 一种高稳定性的靶向接头-药物偶联物
US20240108744A1 (en) * 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
AU662551B2 (en) 1991-08-09 1995-09-07 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CN1113066C (zh) 1995-04-21 2003-07-02 帝国脏器制药株式会社 新型肽衍生物
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
ES2715776T3 (es) * 2004-11-12 2019-06-06 Seattle Genetics Inc Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
KR20140084242A (ko) 2005-06-20 2014-07-04 피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 Ｐｓｍａ 항체-약물 접합체
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
JP5727786B2 (ja) 2007-10-19 2015-06-03 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１９結合性物質およびその使用
CA2718942A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
US8987209B2 (en) 2010-09-29 2015-03-24 Seattle Genetics, Inc. N-carboxyalkyl-auristatin and the use thereof
AU2011316917B2 (en) 2010-10-22 2016-02-25 Seagen Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
ES2531471T3 (es) 2011-02-25 2015-03-16 Lonza Ltd Enlazador ramificado para conjugados de proteínas-fármacos
CA2829736C (en) 2011-03-16 2020-07-21 Seattle Genetics, Inc. N-carboxyalkylauristatins and use thereof
JP2014515753A (ja) 2011-04-21 2014-07-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
CN113527414A (zh) 2011-05-27 2021-10-22 Ambrx公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
AR088694A1 (es) 2011-11-17 2014-06-25 Pfizer Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
US11147852B2 (en) * 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6321633B2 (ja) * 2012-06-04 2018-05-09 ノバルティス アーゲー 部位特異的標識法およびそれによって生成される分子
MX2015010146A (es) * 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.

Also Published As

Publication number Publication date
PT3082877T (pt) 2019-12-03
JP2017503777A (ja) 2017-02-02
US20180244717A1 (en) 2018-08-30
WO2015095301A2 (en) 2015-06-25
US20190382441A1 (en) 2019-12-19
US9988420B2 (en) 2018-06-05
PL3082877T3 (pl) 2020-02-28
AU2014364812B2 (en) 2017-05-25
JP6636925B2 (ja) 2020-01-29
BR112016012538A2 (pt) 2017-09-26
MX2016007865A (es) 2017-01-11
KR20160098257A (ko) 2016-08-18
IL245558A0 (en) 2016-06-30
EP3082877B1 (en) 2019-08-28
US10787480B2 (en) 2020-09-29
ES2758506T3 (es) 2020-05-05
EP3082877A2 (en) 2016-10-26
WO2015095301A3 (en) 2015-09-03
SG11201604877UA (en) 2016-07-28
EP3753578A1 (en) 2020-12-23
AU2014364812A1 (en) 2016-07-07
JP2020023514A (ja) 2020-02-13
IL245558B (en) 2020-01-30
CN105899526A (zh) 2016-08-24
CA2930614A1 (en) 2015-06-25
US10392421B2 (en) 2019-08-27
US20160311853A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
EA201691251A1 (ru) Цитотоксические пептиды и их конъюгаты
EA201692530A1 (ru) Цитотоксические пептиды и их конъюгаты
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
EA201491644A1 (ru) Фармацевтические композиции
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
BR112015019909A2 (pt) Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201791186A1 (ru) Антитела к cd38
EA201290727A1 (ru) Пирролбензодиазепины и их конъюгаты
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MY192248A (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201591843A1 (ru) Способы лечения несовершенного остеогенеза
EA201990839A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
EA201591925A1 (ru) Терапевтические композиции и их применение